Derivative spectrophotometric and fluorimetric methods for determination of rofecoxib in tablets and in human plasma in presence of its photo-degradation product

Farmaco

Volumn 59, Issue 2, 2004, Pages 139-145

  Shehata, Mostafa A ^a   Hassan, Nagiba Y ^a   Fayed, Ahmad S ^a   El Zeany, Badr A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Derivative spectrophotometry; Fluorimetry; Kinetics; Rofecoxib

Indexed keywords

ROFECOXIB;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; FLUORESCENCE; FLUOROMETRY; HALF LIFE TIME; HUMAN; KINETICS; PHOTODEGRADATION; PLASMA; SPECTROPHOTOMETRY; TABLET FORMULATION;

EID: 1042302114     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2003.11.010     Document Type: Article

References (12)

1. Allison M.C., Howatson M.G., Torrance C.I., Lee F.D., Russell R.I. NSAIDs induced gastric ulcers and hemorrhagia upon chronic use. New Engl. J. Med. 327:1992;749-754.
2. Lanza F.L., Rack M.F., Callison D.A., et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel cox-2-selective inhibitor. Gastroenterology. 112:1997;A194.
3. Mao B., Ibrahim A., Ge Z., Ellison D., Hartman R., Prabhu S., et al. Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions. J. Pharm. Biomed. Anal. 28:2002;1101-1113.
4. Woolf E., Fu I., Matulszewski B. Determination of rofecoxib, a cyclooxygenase-2-specific inhibitor in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. J. Chromatogr. B. 730:1999;221-227.
5. Jamali F., Sattari S. HPLC determination of cycloxygenase II inhibitor rofecoxib in rat and human plasma. J. Pharm. Pharm. Sci. 3:2000;307-312.
6. Matthews C.Z., Woolf E.J., Matuszewski B.K. Improved procedure for the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection. J. Chromatogr. A. 949:2002;83-89.
7. Radhakrishna T., Sreeniva D., Om Reddy G. LC determination of rofecoxib in bulk and pharmaceutical formulations. J. Pharm. Biomed. Anal. 26:2001;617-628.
8. Krishna K.V., Moses J.B., Dubey P.K., Chandra B.S., Om Reddy G., Vyas K. Isolation and characterization of process related impurities in rofecoxib. J. Pharm. Biomed. Anal. 29:2002;355-360.
9. Chavez-Eng C.M., Constanzer M.L., Matuszewski B.K. HPLC-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bio-availability studies. J. Chromatogr. B. 767:2002;117-119.
10. Werner U., Werner D., Mondkowski R., Gillich M., Brune K. Selective and rapid LC-MS method for the quantification of rofecoxib in pharmacokinetic studies with humans. J. Chromatogr. B. 760:2002;83-90.
11. Kiang Y.H., Xu W., Kaufman M.J. Ab initio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method. Int. J. Pharm. 252:2003;213-223.
12. Martin A., Swarbrick J., Cammarata A. Physical Pharmacy. third ed :1983;359-360 Lea and Febiger, Philadelphia.